Generic name: LAMIVUDINE 300mg, TENOFOVIR DISOPROXIL FUMARATE 300mg
Dosage form: tablet, film coated
Medically reviewed by Drugs.com. Last updated on Nov 8, 2019.
2.1 Testing Prior to Initiation and During Treatment with TEMIXYS
Prior to initiation treatment with TEMIXYS, test patients for hepatitis B virus infection [see Warnings and Precautions (5.1)].
Prior to initiation and during use of TEMIXYS, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus [see Warnings and Precautions (5.2)].
Recommended Dose for Adult and Pediatric Patients Weighing at Least 35 kg
TEMIXYS is a two-drug fixed-dose combination product containing 300 mg of lamivudine (3TC) and 300 mg of tenofovir disoproxil fumarate (TDF). The recommended dosage of TEMIXYS in HIV-1 infected adult and pediatric patients weighing at least 35 kg is one tablet taken orally once daily with or without food.
Not Recommended in Renal Impairment
Because TEMIXYS is a fixed-dose combination formulation and cannot be dose adjusted, it is not recommended for patients with impaired renal function (creatinine clearance less than 50 mL/min) or patients with end-stage renal disease (ESRD) requiring hemodialysis [see Use in Specific Population (8.6)].
Frequently asked questions
- What is the difference between HIV treatments Symfi and Symfi Lo?
- What drugs are contained in the HIV treatment Cimduo?
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Temixys (lamivudine / tenofovir)
- Side Effects
- During Pregnancy
- Drug Images
- Drug Interactions
- Drug class: antiviral combinations
- FDA Approval History
Other brands: Cimduo